Dr. Mark M. Awad, MD, PhD

  • New York, NY
  • Medical oncologist
NPI1831359355PAC ID0446418438
Medicare services, 2024
219
Medicare patients, 2024
106
Part D claims, 2024
168
Publications
159
Clinical trials
8
Practice address
1275 York Avenue, New York, NY 10065
Professional email
Get professional email
Personal email
Get personal email
Mobile number
Get mobile number
Social profiles

Primary practice

Memorial Sloan Kettering Cancer Center

Hospital · New York, New York

See all 7 affiliations

Find Dr. Awad's professional email, personal email and mobile number

Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.

View contacts for free

Dr. Mark M. Awad is a medical oncologist in New York, New York

Dr. Awad practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Awad's NPI, 1831359355, was assigned on June 10, 2008. Dr. Awad graduated from The Johns Hopkins University School of Medicine in 2008. Dr. Awad holds New York license 333119.

NPI and contact details
Medicare PAC ID
0446418438
NPI enumeration date
June 10, 2008
NPI status
Active
Accepts Medicare assignment
Yes
Offers telehealth
Yes
Professional email
Get email
Personal email
Get email
Mobile number
Get number
Sex
Male
Estimated age
44
Medical school graduation
2008

Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; Dmand AI Affiliation Data; and Doctors and Clinicians National Downloadable File (CMS)

Dr. Mark M. Awad practices at Memorial Sloan Kettering Cancer Center in New York, New York

Dr. Awad's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Source: Dmand AI Affiliation Data

Dr. Mark M. Awad is affiliated with 4 sites of care and 3 medical groups

Dr. Awad's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Cancer Center. Dmand AI also links Dr. Awad to 3 more group practices and clinics and 2 medical groups, each named with a free account.

See all 7 affiliations for Dr. Awad

Sources: Dmand AI Affiliation Data; and Dmand AI Org Hierarchy Data

Dmand AI tracks the EHR system at Dr. Mark M. Awad's practice

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Awad practices, 4 sites in all. Vendor and product names are available with a free account.

EHR by site
SiteEHR vendor and product
Memorial Sloan Kettering Cancer CenterAvailable with a free account
+3 more sites and 2 medical groupsAvailable with a free account

Source: Dmand AI Technology Install Data

For health IT teams

See the EHR and IT leaders at every hospital where Dr. Awad practices

Dmand AI maps EHR vendors, IT decision makers and buying committees across Memorial Sloan Kettering Cancer Center and 6.2K+ hospitals, with verified contacts in the same login.

Dr. Mark M. Awad is one of 458 medical oncologists in New York

Medical oncology is Dr. Awad's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Awad is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Awad's licenses on file in 6 states: New York, Florida, New Jersey, Massachusetts, New Hampshire and Rhode Island.

Specialties and state licenses

  • Medical oncology, New YorkPrimaryLicense 333119 · 2024 to 2026 · taxonomy 207RX0202X
  • Florida licenseSince 2024
  • New Jersey license2024 to 2027
  • Massachusetts license2012 to 2025
  • New Hampshire license2024
  • Rhode Island license2020

Clinical focus

Dmand AI lists breast cancer, chronic anemia, lung cancer and prostate cancer among the conditions Dr. Awad treats.

Medical oncologists near Dr. Awad

Counts of medical oncologists with a Dmand AI profile, by place and practice. Each opens the list.

Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks

Dr. Mark M. Awad billed Medicare for 219 services in 2024

CMS data shows 219 Medicare services from Dr. Awad across 4 procedure codes in 2024, for 106 Medicare patients. Medicare paid $21,162 for them.

Medicare services, 2024219
Medicare patients106
Paid by Medicare$21,162
Procedure codes4

Dr. Awad's Medicare services by type, 2023 to 2024

  • 2023
  • 2024
Office and hospital visits
2023: 4142024: 21947%

Where Dr. Awad's Medicare services took place, 2024

  • In an office12758%
  • In a facility9242%

Dr. Awad compared with the New York median for medical oncologists, 2024

  • Dr. Awad
  • New York median
Medicare services
219vs 34036% below
Medicare patients
106vs 1125% below
Part D claims
82vs 13037% below

Medians across 421 medical oncologists in New York with Dmand AI profiles that report each measure.

Dr. Awad's most billed Medicare procedure codes, 2024

CMS publishes codes billed for 11 or more Medicare patients. Each label is the code family; CPT descriptions are licensed by the AMA.

See all procedures by Dr. Awad

Need commercial claims for Dr. Awad?

Medicare shows one payer. Book a meeting to get commercial claims data for Dr. Awad and other medical oncologists in New York.

Book a meeting

Sources: Medicare Physician & Other Practitioners - by Provider and Service (CMS), 2024 data; and Dmand AI Peer Benchmarks

Dr. Mark M. Awad treated 106 Medicare patients in 2024, average age 73

CMS counts 106 Medicare patients who saw Dr. Awad in 2024. The largest group is 75 to 84, with 46 patients. 75% of them have cancer, and 75% have high blood pressure. 14% are also on Medicaid. Their average risk score is 2.56, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Awad's median patient age at 74, with 56% women.

Medicare patients, 2024106
Average age73
Average risk score2.56
Also on Medicaid14%

Dr. Awad's Medicare patients by age, 2024

CMS leaves out age groups with fewer than 11 patients.

Dr. Awad's Medicare patients by sex, 2024

  • Women5855%
  • Men4845%

Chronic conditions among Dr. Awad's Medicare patients, 2024

  1. Cancer75%
  2. High blood pressure75%
  3. High cholesterol75%
  4. Arthritis46%
  5. Anxiety44%
  6. COPD40%
  7. Ischemic heart disease39%
  8. Mood disorders32%

Share of Medicare patients with each condition. A patient can have several.

Dr. Awad's patients across all payers

Dmand AI patient panel data covers Medicare, Medicaid and commercial patients.

Patient panel by age, all payers

Median age 74

Patient panel by sex, all payers

  • Women56%
  • Men43%

Sources: Dmand AI Patient Panel Data; and Medicare Physician & Other Practitioners - by Provider (CMS), 2024 data

Dr. Mark M. Awad wrote 168 Medicare Part D claims in 2024

In 2024, Dr. Awad wrote 168 Medicare Part D claims for 47 patients. 44% of them were for generic drugs. CMS names the drug for 82 of them, across 5 drugs with 11 or more claims each, at $549,824 in total drug cost. In 2023, CMS named 114 claims across 5 drugs.

Part D claims, 2024168
Drugs named by CMS5
Total drug cost$549,824
Part D patients47

Dr. Awad's Part D claims by kind of drug, 2024

  • Generic74 claims44%
  • Brand-name94 claims56%

Dr. Awad's most prescribed drugs by claims, 2024

CMS names a drug when it has 11 or more claims. Share is of the claims for drugs CMS names.

Part D claims for drugs CMS names, 2023 to 2024

  • 2023
  • 2024
Claims for drugs CMS names
2023: 1142024: 8228%

Drugs named by CMS: 5 in 2024, 5 in 2023.

See all prescribing by Dr. Awad

Sources: Medicare Part D Prescribers - by Provider and Drug (CMS), 2024 data, released May 6, 2026; and Medicare Part D Prescribers - by Provider (CMS), 2024 data

Dr. Mark M. Awad scored 84 out of 100 in Medicare's MIPS program for 2024

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Awad for performance year 2024, reported as part of a group. Dr. Awad accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Awad as offering telehealth.

Accepts Medicare assignment
Yes
Offers telehealth
Yes

Dr. Awad's MIPS scores, performance year 2024

  • 84of 100Final score
  • 65of 100Quality
  • 100of 100Promoting Interoperability
  • 40of 100Improvement Activities
  • 69of 100Cost

Each score is out of 100. The final score weighs the categories CMS scored for this clinician.

Sources: Doctors and Clinicians National Downloadable File (CMS); and Clinician Public Reporting: Overall MIPS Performance (CMS), 2024 data, released September 10, 2026

For MedTech and pharma teams

Find medical oncologists like Dr. Awad by procedure volume and prescribing

Filter 7.4M+ HCPs by Medicare procedures, Part D drugs and Open Payments history, then reach them with verified contacts in one login.

Dr. Mark M. Awad has 159 publications on record

Dmand AI links 159 papers to Dr. Awad, published from 2006 to 2025. 2020 was the busiest year, with 20. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Antineoplastic Combined Chemotherapy Protocols. Dr. Awad has published most often in Clin Cancer Res. Dr. Awad's most frequent co-authors are Biagio Ricciuti, Matthew D. Hellmann, MD and Victor Renault Vaz, MD.

Papers159
Years published2006 to 2025

Dr. Awad's papers by year, 2016 to 2025

Topics Dr. Awad writes about most

  • Lung Neoplasms
  • Carcinoma, Non-Small-Cell Lung
  • Antineoplastic Combined Chemotherapy Protocols
  • B7-H1 Antigen
  • Immune Checkpoint Inhibitors
  • Immunotherapy
  • Biomarkers, Tumor
  • Antibodies, Monoclonal, Humanized

Dr. Awad's most frequent co-authors

Recent publications by Dr. Awad

See all 159 publications and co-authors

See who Dr. Awad researches with

Physician Network Discovery turns co-authorship, shared hospitals and shared groups into a map of who Dr. Awad works with, so you can find a warm path to the right medical oncologists.

How network discovery works

Sources: PubMed (National Library of Medicine); and Dmand AI Research Linkage

Dr. Mark M. Awad has worked on 8 clinical trials

Dmand AI links Dr. Awad to 8 clinical trials. 5 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Deafness, Autosomal Recessive 39. Dana-Farber Cancer Institute sponsors the most, 3. Open Payments lists research payments to Dr. Awad that name 2 trials.

Clinical trials with Dr. Awad by phase

  1. 1Phase 1: 1 trial
  2. 1Phase 1/2: 1 trial
  3. 1Phase 2: 1 trial
  4. 1Phase 3: 1 trial
  5. NonePhase 4: no trials

Conditions in Dr. Awad's trials

  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma, Bronchogenic
  • Deafness, Autosomal Recessive 39
  • Mesothelioma
  • Squamous Cell Carcinoma of Head and Neck

Investigators on the most trials with Dr. Awad

Recent clinical trials with Dr. Awad

See all 8 clinical trials and co-investigators

Sources: Dmand AI Research Linkage; and ClinicalTrials.gov (National Library of Medicine)

Dr. Mark M. Awad received $258,445 in industry payments from 2016 to 2025

CMS Open Payments shows 204 general payments to Dr. Awad from 26 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 75% of the total. Merck Sharp & Dohme Corporation paid the most, $65,892. It also lists 15 research payments totaling $45,059 from 2017 to 2024, naming 2 clinical trials.

General payments to Dr. Awad by program year, 2016 to 2025

General payments to Dr. Awad by kind, 2016 to 2025

$258.4Kin total
  • Consulting fees$193,03775%
  • Travel and lodging$31,99312%
  • Speaker and faculty fees$22,9949%
  • Honoraria$6,5003%
  • Other$3,9202%

Companies that paid Dr. Awad the most, 2016 to 2025

Share is of all general payments to this clinician.

See all payments to Dr. Awad

Source: Open Payments (CMS), 2025 data, released July 7, 2026

Dr. Mark M. Awad graduated from The Johns Hopkins University School of Medicine

Dr. Awad graduated from The Johns Hopkins University School of Medicine in 2008.

  1. Medical schoolThe Johns Hopkins University School of Medicine
  2. Board certified in medical oncologyAmerican Board of Internal Medicine

Source: Dmand AI Professional Profile Data

Dr. Mark M. Awad accepts plans from 7 insurance carriers

Dr. Awad is in network with 7 carriers, including Aetna, Excellus BlueCross BlueShield and Molina. Medicare plans come from the most carriers, 4. Check the plan with the practice before a visit.

  • Aetna
  • Excellus BlueCross BlueShield
  • Molina
  • MVP Health Care
  • CMS Medicare
  • NY State Medicaid
  • RI State Medicaid

Plan types Dr. Awad accepts, by number of carriers

  1. Medicare4
  2. EPO3
  3. Medicaid3
  4. PPO3
  5. HMO2
  6. POS1

Source: Dmand AI Insurance Network Data

Sources for Dr. Mark M. Awad's profile data

Sources for the data on this page
Data on this pageSource
NPI, name, sex, specialty and licensesNPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Professional Profile Data
Practice locations and phoneDmand AI Affiliation Data
Primary practice, affiliations and health systemDmand AI Affiliation DataDmand AI Org Hierarchy Data
Medicare services and procedure codesMedicare Physician & Other Practitioners - by Provider and Service (CMS) (opens in a new tab)
State medians for the same specialtyDmand AI Peer Benchmarks
Medicare patients and the all-payer patient panelDmand AI Patient Panel DataMedicare Physician & Other Practitioners - by Provider (CMS) (opens in a new tab)
Part D prescribingMedicare Part D Prescribers - by Provider and Drug (CMS) (opens in a new tab)Medicare Part D Prescribers - by Provider (CMS) (opens in a new tab)
MIPS scores, telehealth, assignment and procedure percentilesDoctors and Clinicians National Downloadable File (CMS) (opens in a new tab)Clinician Public Reporting: Overall MIPS Performance (CMS) (opens in a new tab)
Publications, topics and co-authorsPubMed (National Library of Medicine) (opens in a new tab)Dmand AI Research Linkage
Clinical trials and co-investigatorsDmand AI Research LinkageClinicalTrials.gov (National Library of Medicine) (opens in a new tab)
Industry paymentsOpen Payments (CMS) (opens in a new tab)
Training, board certification and membershipsDmand AI Professional Profile Data
Insurance carriers and plan typesDmand AI Insurance Network Data
EHR at each practice siteDmand AI Technology Install Data
Similar physiciansDmand AI Affiliation Data

Data last refreshed October 2026Report an inaccuracyRemove my information

FAQ

Frequently asked questions about Dr. Mark M. Awad

Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.

What is Dr. Mark M. Awad's NPI number?

Dr. Mark M. Awad's NPI number is 1831359355. It was assigned on June 10, 2008, and it is active in the NPI Registry.

What kind of doctor is Dr. Mark M. Awad?

Dr. Mark M. Awad is a medical oncologist in New York, New York. The primary specialty in the NPI Registry is Medical Oncology Physician (taxonomy code 207RX0202X).

Where does Dr. Mark M. Awad practice?

Dr. Awad practices at 1275 York Avenue, New York, NY 10065. Dr. Awad's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. Dmand AI also links Dr. Awad to 3 group practices and clinics and 2 medical groups.

What is Dr. Mark M. Awad's medical license number?

Dr. Awad holds New York license 333119, one of the licenses on file in 6 states.

Which states has Dr. Mark M. Awad been licensed in?

Dmand AI has state licenses on file for Dr. Awad in New York (2024 to 2026), Florida (since 2024), New Jersey (2024 to 2027), Massachusetts (2012 to 2025), New Hampshire (2024) and Rhode Island (2020).

Which hospitals is Dr. Mark M. Awad affiliated with?

Dr. Awad practices at Memorial Sloan Kettering Cancer Center in New York, New York.

What medical group is Dr. Mark M. Awad part of?

Dr. Awad is linked to Memorial Sloan Kettering Cancer Center. Dmand AI links Dr. Awad to 2 more medical groups.

Does Dr. Mark M. Awad accept Medicare?

Yes. CMS data shows Dr. Awad billed Medicare for 219 services in 2024, and Dr. Awad accepts Medicare assignment.

Does Dr. Mark M. Awad offer telehealth?

Yes. The CMS Doctors and Clinicians file lists Dr. Awad as offering telehealth services.

What is Dr. Mark M. Awad's MIPS score?

Dr. Awad's MIPS final score for performance year 2024 is 84 out of 100, reported as part of a group.

Show 10 more questionsShow fewer questions

How many Medicare patients does Dr. Mark M. Awad see?

CMS counts 106 Medicare patients who saw Dr. Awad in 2024, with an average age of 73.

Is Dr. Mark M. Awad board certified?

Yes. Dr. Awad is board certified in medical oncology by the American Board of Internal Medicine.

What services does Dr. Mark M. Awad bill to Medicare?

In 2024, Dr. Awad's most billed Medicare services were office visit, established patient (99215), office visit, established patient (99214) and hospital inpatient care (99232).

Where did Dr. Mark M. Awad go to medical school?

Dr. Awad graduated from The Johns Hopkins University School of Medicine in 2008.

What drugs does Dr. Mark M. Awad prescribe most?

In 2024 Medicare Part D data, Dr. Awad's most prescribed drugs by claims were Dexamethasone, Eliquis and Tagrisso.

Has Dr. Mark M. Awad received payments from drug or device companies?

CMS Open Payments shows $258,445 in general payments to Dr. Awad from 26 companies from 2016 to 2025. The largest total came from Merck Sharp & Dohme Corporation.

How long has Dr. Mark M. Awad been practicing?

Dr. Awad graduated from medical school in 2008, 18 years ago.

Does Dr. Mark M. Awad do research?

Dmand AI links 159 publications to Dr. Awad, published from 2006 to 2025. Dr. Awad has worked on 8 clinical trials.

Who does Dr. Mark M. Awad publish with?

Dr. Awad's most frequent co-authors are Biagio Ricciuti (55 shared papers), Matthew D. Hellmann, MD (15 shared papers) and Victor Renault Vaz, MD (14 shared papers).

What insurance does Dr. Mark M. Awad accept?

Dr. Awad is in network with 7 carriers, including Aetna, Excellus BlueCross BlueShield and Molina. Medicare plans come from the most carriers, 4. Check the plan with the practice before a visit.

Selling to medical oncology practices?

See medical oncologists in New York by site of care and group

Find the practices, groups and hospitals they work with, and the right people to contact at each.

  • 30 days free
  • Self-serve
  • No credit card

Cookie settings

Turn each category on or off. Your choice is kept for 12 months and you can change it here at any time.

Necessary

Always on. Sign-in, security, downloads you asked for, your cookie choice, and the page that led to a signup.

View cookies (6)
  • dm_consentDmand AI. Your cookie choices and whether your browser sent a Global Privacy Control signal. 12 months.
  • dm_ft, dm_ltDmand AI. The first and the latest page you arrived on, with the date, so a signup is credited to the page that worked. 90 days, 30 days.
  • dm_fs, dm_lsDmand AI. The first and the latest source of a visit (a search engine, a campaign or the site that linked here). 90 days, 30 days.
  • dm_dl, dm_dl_okDmand AI. After you give an email address for a download, lets you download files without being asked again. 30 days.
  • Session and CSRF cookiesDmand AI (app.dmand.ai). Sign-in and form protection in the application. Session.
  • __cf_bm, cf_clearanceCloudflare. Tells people from automated traffic and keeps the site available. 30 minutes; cf_clearance while a security check is valid.

Analytics

On unless you turn it off. How pages are used, in aggregate, and recordings of how pages are used.

View cookies (6)
  • Google Tag ManagerGoogle. Loads the analytics and marketing tags that are on. Sets no cookie of its own and does not load when both categories are off. n/a.
  • _ga, _ga_<container-id>Google Analytics 4. Visits and page views in aggregate on dmand.ai. 2 years.
  • _clck, _clskMicrosoft Clarity. Recordings and heatmaps of how pages are used, with form fields masked. 1 year, 1 day.
  • CLID, MUID, ANONCHK, MR, SMMicrosoft (clarity.ms). Set by Microsoft when Clarity loads, to recognize a browser across sites that use Clarity. Up to 1 year.
  • None (cookieless)Ahrefs Analytics. Page views in aggregate. n/a.
  • ph_<project>_posthogPostHog. Product usage, errors and performance in app.dmand.ai, used to fix bugs and improve features. 365 days.

Marketing

On unless you turn it off, and always off when your browser sends a Global Privacy Control signal. A visitor identification service tells our sales team which companies and people visit.

View cookies (6)
  • _reb2buid, _reb2butkRB2B. Recognizes a returning browser for visitor identification. 360 days, 1 year.
  • _reb2bgeoRB2B. The location used to decide whether a visit can be identified. 20 days.
  • _reb2brefRB2B. The page or site that referred the visit. 15 days.
  • _reb2bfxf, _reb2btd, _reb2bliRB2B. Links the visit to an identified business profile. 1 month.
  • _reb2bresolveRB2B. Holds a match while it is being resolved. 2 days.
  • _reb2sessionID, _reb2bloadedRB2B. The current visit, and a guard against loading the script twice. 30 minutes, 1 second.

Functional

On unless you turn it off. Remembers choices such as a collapsed section.

View cookies (none today)